Glaukos Corp income statement

In fiscal 2025, Glaukos Corp reported revenue of $507m, up 32.3% on the year before, operating income of −$200m (a -39.3% margin) and net income of −$188m, or −$3.28 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Glaukos Corp: income statement, annual
Fiscal year	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	21	46	72	114	159	181	237	225	294	283	315	383	507	690
Cost of revenue	—	—	—	16	21	25	39	92	67	69	76	94	112	130
Gross profit	18	34	59	98	138	156	198	133	227	214	239	289	283	447
Research and development	16	19	25	29	39	50	68	85	101	123	139	136	151	201
Selling, general and administrative	17	28	44	65	96	120	177	171	179	193	224	261	332	435
Operating income	−14	−13	−10	4	−2	−13	−50	−124	−33	−82	−129	−122	−200	−176
Interest expense	—	—	—	—	—	—	3	14	13	14	14	10	5	5
Income before tax	−14	−14	−38	5	0	−12	−50	−132	−49	−98	−134	−146	−193	−175
Income tax	0	0	0	0	0	1	−65	−12	0	1	1	1	−5	−5
Net income	−13	−12	−37	5	−0	−13	15	−120	−50	−99	−135	−146	−188	−170
Diluted EPS	−$0.39	−$0.33	−$1.06	$0.12	$0.00	−$0.37	$0.37	−$2.70	−$1.07	−$2.09	−$2.78	−$2.77	−$3.28	−$2.88
Diluted shares (average)	33m	37m	35m	36m	34m	35m	41m	44m	46m	47m	48m	53m	57m	59m
EBITDA	−13	−9	−6	9	3	−7	−44	−94	−3	−51	−95	−87	−162	−134

US$ millions unless shown otherwise. Fiscal quarters.

Glaukos Corp: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	105	107	124	134	143	151	186	211
Cost of revenue	29	24	27	29	32	33	34	31
Gross profit	77	82	97	105	−2	117	152	180
Research and development	37	32	37	27	75	44	51	31
Selling, general and administrative	69	71	83	83	95	93	116	131
Operating income	−29	−21	−23	−16	−140	−20	−17	1
Interest expense	2	1	1	1	1	1	1	1
Income before tax	−34	−18	−19	−16	−140	−19	−18	2
Income tax	−0	0	0	0	−6	0	1	0
Net income	−34	−18	−20	−16	−134	−20	−18	2
Diluted EPS	−$0.59	−$0.32	−$0.34	−$0.28	−$2.33	−$0.34	−$0.31	$0.03
EBITDA	−20	−12	−14	−7	−128	−8	−8	10

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: GKOS vs TMDX GKOS vs NVCR GKOS vs MYGN BVS vs GKOS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Glaukos Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Glaukos Corp.